

Survey of 275 Patients and Caregivers Affected By Pyruvate Kinase Deficiency: Impact of Communication with Hematologists on Mental Health and Quality of Life

Rachael F. Grace, MD¹ and Wilma Barcellini, MD²

¹Dana-Farber/ Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA; ²Hematology Unit, Pathophysiology of Anemias Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

No. of

respondents

11

31

19

11

2

Background

Survey Results

Α

Age of

respondents

18-30 years

31-40 years

41-50 vears

51-60 years

>60 years


- · Pyruvate kinase deficiency (PKD) is a rare congenital hemolytic anemia affecting approximately 3 people per million globally^{1,2}
- · Currently, there are no disease-modifying treatments; management focuses on supportive blood transfusions, iron chelation, and in severe cases splenectomy.³ but new disease-targeted therapies are in development
- PKD has a wide-ranging impact on guality of life (QoL).⁴ Patient advocacy and patient-reported outcomes research has been limited³
- The PKD Advocacy Advisory Council (AAC), a group of patients and caregivers, advocates, and physicians, was formed in 2020, by Agios Pharmaceuticals, to improve both timely diagnosis and access to education, support and care for individuals with PKD

Objective

Collect the opinions of patients and caregivers affected by PKD about communication with their hematologists to raise awareness about living with PKD and improve future practices and outcomes

Methods

- · A global web-based survey was conducted between Jan-Feb 2021 to improve understanding of PKD and its disease burden
- · Two versions were developed: one for adult patients and another for caregivers providing unpaid care toa PKD patient
- · The survey included respondents from 11 countries, including France, Germany, Italy, the UK and US
- · Survey questions were closed-ended, multiple choice, Likert scale and binary choice plus free text
- . The survey was carried out according to British Healthcare Business Intelligence Association Legal and Ethical Guidelines, as well as guidelines established by UK Market Research Society
- Participants were recruited via online panels and AAC member channels, including PKD Facebook groups
- The survey covered: (1) information provided at time of diagnosis, (2) treating hematologist's knowledge of the condition, (3) level of communication with the hematologist and (4) the patient's or caregiver's relationship with the hematologist



56% reported their hematologist can answer PKD-management guestions and 44% reported that their

• 29% reported at least one negative emotion including worried (21%), anxious (17%), and depressed

62% of NTPs vs. 82% receiving ≥ 1 transfusion/year reported that their hematologist manages their

• 51% of NTPs vs. 83% receiving ≥ 1 transfusion/vear state their hematologist understands the impact of

• 44% of NTPs vs. 75% receiving ≥ 1 transfusion/year state their hematologist considers their perspective

· Majority of patients have questions on the effects of PKD with age but less than half report that their

25% reported feeling neither positive nor negative, or somewhat negative, after interactions

Communication was negatively reported amongst non-transfused patients (NTPs) (Figure 3)

(17%) - the survey reveals an unmet need in emotional and psychosocial support

Abstract #152326

Figure 1. Distribution of study participants by age. (A) Patients; (B) Caregivers

survey, making it the largest within the community to date (Figure 1)

В

Age of

respondents

18-30 years

31-40 years

41-50 vears

51-60 years

>60 years

• Half of the patients had been diagnosed for >10 years

No, of

respondents


33

72

56

34

5



My hematologist is able My hematologist can My hematologist searchs to answer my questions explain potential health for and finds solutions to about how PKD is complications associated optimize the with my PKD management of my PKD managed All respondents Patients Caregivers

Figure 2. Impression of PKD management among patients & caregivers

Conclusions

- Survey results highlight a need to adapt clinical approaches to improve outcomes
- Hematologists should seek to improve their PKD understanding and optimize care and support of non-transfused patients
- · Care should be holistic and consider emotional and psychosocial health aspects
- · Clinicians should consult with other medical specialists, including hematologists specializing in PKD to monitor and manage complications effectively
- · Further research is necessary to build on the survey insights, increase awareness, and inform approaches to improve outcomes

Consideration of perspectives.

condition well (P=0.003)

PKD on their QoL (P<0.001)

hematologist discusses this topic

hematologist had profound PKD-related knowledge

regarding their PKD management plan (P<0.001)

Author acknowledgments: We thank the members of AAC and the survey respondents who made this work possible

Disclosures: R.F. Grace: Agios, Novartis, Dova - research funding; Dova, Principia - membership on an entity's Board of Directors or advisory committees. W. Barcellini: Agios, Alexion. Novartis - honoraria: Agios - research funding: Bioverativ. Incyte - board membership or advisory committee. This study and white paper were sponsored by Agio Pharmaceuticals, Inc. Editorial support was provided by FleishmanHillard, paid for by Agios,

Interested in learning more? Scan the QR code for additional information



Dana-Farber

Boston Children's



^{1.} Grace, R.F. Lavton, D. Barcellini, W. (2019). How we manage patients with pyruvate kinase deficiency. British Journal of Haematology, 184 (5), 721-734 2 Corey, P.J., Charder, J., Hendrick, A., Reid, M.M., Saunders, P.W., Imagain, H., Taylor, P.R. & Weit, N. (2000). Prevalence of provide kinase deficiency in northern tecropresp possibilition in the north of Englined. Nathern Region: Network Region Network Region Network Region Network Region Networks (2003). Voloci of the Patient Report. Available at: <u>https://aradionaes.org/biol/dofaethyl_last_accessed_sub-regional_accessed_sub-regionaccessed_sub-region</u>